Recently, the FDA approved the HIF-2α inhibitor belzutifan for treating certain cancers associated with von Hippel–Lindau disease, such as renal cell carcinoma, hemangioblastoma, and pancreatic neuroendocrine tumors [164]. Here, EPAS1 is linked to hemangioblastoma.